Saturday, 31 October 2026European Markets

BORGESTAD Stock Was 10.71% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with BORGESTAD (BOR.OL) rising 10.71% to kr0.31 on Tuesday, after two successive sessions in a row of gains. Oslo Børs Benchmark Index_GI fell 0.72% to kr1,299.63, following the last session's upward trend on what was a somewhat negative trend exchanging session today.

BORGESTAD's last close was kr0.28, 86.14% below its 52-week high of kr2.02.

About BORGESTAD

Borgestad ASA develops, manufactures, distributes, and installs refractory products in Norway. The company also develops and manages real estate properties. Its properties include Agora Bytom, a shopping center with a gross area of 52,000 square meters and a rental area of approximately 30,000 square meters, as well as a parking garage with 820 parking lots in Poland. Borgestad ASA was founded in 1904 and is headquartered in Skien, Norway.

Earnings Per Share

As for profitability, BORGESTAD has a trailing twelve months EPS of kr-0.3.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -15.11%.

Volume

Today's last reported volume for BORGESTAD is 2029500 which is 215.74% above its average volume of 642762.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BORGESTAD's stock is considered to be oversold (<=20).

Yearly Top and Bottom Value

BORGESTAD's stock is valued at kr0.31 at 21:31 EST, way below its 52-week low of kr1.23.

More news about BORGESTAD (BOR.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com